MedTrace Logo

Bariatric Surgery and Pharmacokinetics of Candesartan

NCT03460327 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2025-06-06

No results posted yet for this study

Summary

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on candesartan are investigated.

Conditions

  • Obesity, Morbid

Interventions

DRUG

Candesartan

Patients are tested for their normal prescription candesartan medication

Sponsors & Collaborators

  • St. Olavs Hospital

    collaborator OTHER

  • Volvat Medisinsk Senter Stokkan

    collaborator OTHER

  • Namsos Hospital

    collaborator OTHER

  • Alesund Hospital

    collaborator OTHER

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Magnus Strømmen, MSc · St. Olavs University Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-02
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460327 on ClinicalTrials.gov